Switch theme
Sign up to access all valuation multiples
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AmnioWrap2.
2006
20
LTM Revenue $328M
Last FY EBITDA $31.5M
$169M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioStem Technologies has a last 12-month revenue (LTM) of $328M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, BioStem Technologies achieved revenue of $302M and an EBITDA of $31.5M.
BioStem Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioStem Technologies valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $328M | XXX | $302M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $288M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 95% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $31.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 10% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $31.2M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $31.9M | XXX | $31.9M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, BioStem Technologies's stock price is $11.
BioStem Technologies has current market cap of $188M, and EV of $169M.
See BioStem Technologies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $169M | $188M | XXX | XXX | XXX | XXX | $1.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, BioStem Technologies has market cap of $188M and EV of $169M.
BioStem Technologies's trades at 0.6x EV/Revenue multiple, and 5.4x EV/EBITDA.
Equity research analysts estimate BioStem Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioStem Technologies has a P/E ratio of 5.9x.
See valuation multiples for BioStem Technologies and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $188M | XXX | $188M | XXX | XXX | XXX |
| EV (current) | $169M | XXX | $169M | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 5.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 5.9x | XXX | 5.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 7.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioStem Technologies's last 12 month revenue growth is 7%
BioStem Technologies's revenue per employee in the last FY averaged $15.1M, while opex per employee averaged $12.8M for the same period.
BioStem Technologies's rule of 40 is -34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioStem Technologies's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioStem Technologies and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -34% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $15.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $12.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 78% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 85% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioStem Technologies acquired XXX companies to date.
Last acquisition by BioStem Technologies was XXXXXXXX, XXXXX XXXXX XXXXXX . BioStem Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BioStem Technologies founded? | BioStem Technologies was founded in 2006. |
| Where is BioStem Technologies headquartered? | BioStem Technologies is headquartered in United States of America. |
| How many employees does BioStem Technologies have? | As of today, BioStem Technologies has 20 employees. |
| Is BioStem Technologies publicy listed? | Yes, BioStem Technologies is a public company listed on PINX. |
| What is the stock symbol of BioStem Technologies? | BioStem Technologies trades under BSEM ticker. |
| When did BioStem Technologies go public? | BioStem Technologies went public in 2008. |
| Who are competitors of BioStem Technologies? | Similar companies to BioStem Technologies include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of BioStem Technologies? | BioStem Technologies's current market cap is $188M |
| What is the current revenue of BioStem Technologies? | BioStem Technologies's last 12 months revenue is $328M. |
| What is the current revenue growth of BioStem Technologies? | BioStem Technologies revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of BioStem Technologies? | Current revenue multiple of BioStem Technologies is 0.5x. |
| Is BioStem Technologies profitable? | Yes, BioStem Technologies is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
